Skip to content

Study on immune microenvironment index and radiotherapy effect of cervical carcinoma

Study on immune microenvironment index and radiotherapy effect of cervical carcinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400089547
Enrollment
Unknown
Registered
2024-09-10
Start date
2022-11-03
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer

Interventions

Observed group:This experiment is an observational study and does not involve any intervention measures.

Sponsors

Capital Medical University Cancer Canter, Beijing Shijitan Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Age =18 years old; 2) female; 3) Cervical cancer diagnosed by pathology (including histology or cytology); patients with clinical stage of cervical cancer (FIGO stage) IB3, II-IVA; 4) ECOG PS: 0-2 points; 5) Expected survival period = 6 months; 6) Subjects voluntarily joined the study, signed a written informed consent before any trial-related procedures were implemented, and had good compliance and cooperated with follow-up; 7) All organ functions are basically normal (laboratory test results within one week before enrollment without continuous supportive treatment): white blood cells>3.5 × 10 ^ 9/L, neutrophils>1.5 × 10 ^ 9/L, platelets>100 × 10 ^ 9/L, hemoglobin>9.0g/dl; AST (SGOT), ALT (SGPT)<2.5 × ULN;

Exclusion criteria

Exclusion criteria: 1) Patients without pathological diagnosis; 2) Currently participating in interventional clinical research treatment, or receiving treatment with other investigational drugs or investigational devices within 8 weeks before radiotherapy; 3) Class III-IV congestive heart failure (New York Heart Association classification), poorly controlled and clinically significant arrhythmias; 4) Known mental illness or substance abuse that may affect compliance with trial requirements; 5) Known history of human immunodeficiency virus (HIV) infection (ie HIV 1/2 antibody positive), active pulmonary tuberculosis; 6) Patients undergoing total cervical resection; 7) Suffering from other tumor diseases at the same time. 8) Investigators deem unsuitable for inclusion.

Design outcomes

Secondary

MeasureTime frame
Progression-Free Survival, PFS;Overall Survival, OS;

Primary

MeasureTime frame
Objective Response Rate, ORR;

Countries

China

Contacts

Public ContactLinan Song

Capital Medical University Cancer Canter, Beijing Shijitan Hospital

sln_sjt@sina.com+86 189 1020 5251

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026